43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial
Titel:
43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial
Auteur:
Dang, C. Ewer, M.S. Delaloge, S. Ferrero, J-M. Colomer, R. de la Cruz Merino, L. Dadswell, K. Verrill, M. Eiger, D. Sarkar, S. de Haas, S. Restuccia, E. Swain, S.M.